NCT00432211Unknown2 期
A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
Renovo1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Investigator scar assessment
研究概览
简要总结
This study is being undertaken to investigate the efficacy and safety of Juvista (given as an intradermal injection of 200ng/100µl per linear centimetre of wound margin) in the prevention or improvement of scar appearance when administered intradermally to approximated wound margins following surgical scar revision.
In addition, this study will compare the scar revision techniques of complete excision (excision of the entire scar during one surgical procedure) and staged excision (excision of the outmost segments and central core separately).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged 18-85 years who have provided written informed consent.
- •A body mass index between 15 and 35 kg/m2 .
- •Subjects with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.
- •Female subjects of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until one month after administration of the final study dose.
- •Subjects with linear scars that, in the opinion of the Investigator, are suitable for revision by excision and direct closure. The area of scar to be revised must be at least 5cm in length and have at least two comparable areas.
- •Subjects, who, in the opinion of the Investigator have stabilised, mature scars.
排除标准
- •Subjects who on direct questioning and physical examination have history or evidence of keloid scarring.
- •Subjects with scars for revision that cross a joint or are in close proximity to an anatomical structure, which could lead to distortion of the resultant scar.
- •Subjects with additional scars less than 3cm away from the area to be revised.
- •Subjects with a history of a bleeding disorder.
- •Subjects with diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerability or efficacy.
- •Subjects who have had surgery in the area to be excised within one year of Day
- •Subjects with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
- •Subjects who on direct questioning and / or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.
- •Subjects with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
- •Subjects who are taking, or have taken, any investigational drugs including Juvista within 3 months prior to the screening visit.
- •Subjects who are taking regular, continuous, oral corticosteroid therapy.
- •Subjects who, in the opinion of the Investigator, have significant ongoing psychiatric disorders, which may interfere with the trial assessments / visits.
- •Subjects undergoing investigations or changes in management for an existing medical condition.
- •Subjects who are or who become pregnant up to and including Day 0 or who are lactating.
- •In the opinion of the Investigator, a subject who is not likely to complete the trial for whatever reason.
研究组 & 干预措施
1
Placebo Comparator
Complete Scar Excision
干预措施: Avotermin (Drug)
2
Placebo Comparator
Staged Excision of scar
干预措施: Avotermin (Drug)
结局指标
主要结局
Investigator scar assessment
时间窗: up to 7 month visit
Patient scar assessment
时间窗: up to 7 month visit
Independent scar assessment
时间窗: up to month 7
次要结局
- Local tolerability(up to month 7)
- Adverse events(up to month 7)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe KeloidsKeloidNCT00836147Renovo20
已完成
2 期
Juvista (Avotermin) in Scars Following Varicose Vein RemovalVaricose VeinsCicatrixNCT00430326Renovo156
已完成
3 期
Juvista in Scar Revision Surgery of Disfiguring ScarsCicatrixNCT00742443Renovo350
已完成
1 期
Safety of Juvista When Administered Following Excision of Ear Lobe KeloidsKeloidNCT00710333Renovo10
已完成
1 期
Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid ScarsKeloidNCT00469235Renovo20